iRhythm Technologies Inc. (IRTC) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

iRhythm Technologies Inc. (IRTC)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

99.01

4.42 (4.67%)

At close: Jan 14, 2025, 3:59 PM

99.01

0.00%

After-hours Jan 14, 2025, 04:00 PM EST

undefined% (undefined)

Bid	96.01
Market Cap	3.10B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-4.85
PE Ratio (ttm)	-20.41
Forward PE	n/a
Analyst	Buy

Ask	157.42
Volume	733,633
Avg. Volume (20D)	488,880
Open	96.51
Previous Close	94.59
Day's Range	94.76 - 101.23
52-Week Range	55.92 - 124.11
Beta	undefined

About IRTC

iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. It offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias. The company's Zio XT and AT monito...

[Show more]

Industry Medical - Devices

Sector Healthcare

IPO Date Oct 20, 2016

Employees 2,000

Stock Exchange NASDAQ

Ticker Symbol IRTC

Website https://www.irhythmtech.com

Analyst Forecast

According to 11 analyst ratings, the average rating for IRTC stock is "Buy." The 12-month stock price forecast is $111, which is an increase of 12.11% from the latest price.

Buy 72.73%

Hold 18.18%

Sell 0.00%

Stock Forecasts

Next Earnings Release

iRhythm Technologies Inc. is scheduled to release its earnings on Feb 20, 2025, during market hours.
Analysts project revenue of $157.28M, reflecting a 18.69% YoY growth and earnings per share of -0.23, making a -72.62% decrease YoY.

Why Price Moved

1 day ago · Source New

-3.18%

iRhythm Technologies shares are trading lower. The... Unlock content with Pro Subscription

2 months ago · Source

+3.59%

iRhythm Technologies shares are trading higher. Baird maintained an Outperform rating on the stock.

News

1 month ago · marketbeat.com

Top 3 Robotics and Automation Stocks for the Next AI Boom

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.

1 month ago · https://thefly.com

iRhythm resumed with an Equal Weight at Wells Fargo

Wells Fargo analyst Nathan Treybeck resumed coverage of iRhythm with an Equal Weight rating and $86 price target. The analyst believes stock upside will be limited until there is greater certainty on ...

2 months ago · seekingalpha.com

iRhythm Technologies, Inc. (IRTC) Q3 2024 Earnings Call Transcript

iRhythm Technologies, Inc. (NASDAQ:IRTC ) Q3 2024 Results Conference Call October 30, 2024 4:30 PM ET Company Participants Stephanie Zhadkevich - Director, Investor Relations Quentin Blackford - Presi...

2 months ago · zacks.com

IRhythm Technologies (IRTC) Reports Q3 Loss, Tops Revenue Estimates

IRhythm Technologies (IRTC) came out with a quarterly loss of $1.26 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to loss of $0.89 per share a year ago.

2 months ago · zacks.com

iRhythm Technologies (IRTC) Soars 21.7%: Is Further Upside Left in the Stock?

iRhythm Technologies (IRTC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength...

2 months ago · benzinga.com

With FDA Approval iRhythm May Be Able To Lift Regulatory Overhang, Investor Skepticism, Analyst Says

On Monday, the FDA approved iRhythm Technologies, Inc.'s IRTC 510(k) submission related to prior design changes to the Zio AT device via letter to file.

2 months ago · zacks.com

iRhythm Technologies Stock Rises Post FDA Clearance for Zio AT

IRTC receives FDA 510(k) clearance for prior design modifications to its Zio AT device, reinforcing its commitment to quality and compliance.